Listed by the USPTO as ROZOF, TIMOTHY R
Tech Center 1600 • Art Units: 1625
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18885092 | COMPOUND AND LIPID COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 18815847 | COMPOSITION FOR LIVING BODY | Non-Final OA | FUJIFILM Corporation |
| 18837494 | INSECT, ACARINA AND NEMATODE PEST CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18886532 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | Non-Final OA | KOWA COMPANY, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.7% of resolved applications examined by Timothy R Rozof were allowed (974 resolved cases), compared with 51.6% across Art Unit 1625 over the last five years.
This examiner's interview lift is +23.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Timothy R Rozof took 738 days on average from filing to allowance.
Timothy R Rozof examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
